Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Kite Pharma

Biotech & Life Sciences · Santa Monica, United States · Founded 2009 · IPO 2014 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$12B
Market cap · 2026
Revenue
$20M
Latest reported FY
Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026

Immune-based therapies to treat cancer indications

Investors

4 investors on Kite Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Riverbank Capital Securities
Alta Partners
Two River
Series B+ 1 investor entered at this stage
Arie Belldegrun

Global footprint

Where Kite Pharma has talent and traffic

AI talent share
0.4% of workforce is AI talent
(16 of 4,007 staff)
Core AI20.05%
Other AI140.35%
Non-AI workforce3,99199.6%
Workforce by country
33 countries with
team presence
🇺🇸 United States66.6%
🇳🇱 Netherlands24.4%
🇬🇧 United Kingdom2.4%
🇪🇸 Spain0.9%
🇮🇪 Ireland0.9%
Top 5 of 33 shown
Web traffic by country
19K monthly visits
across markets
🇺🇸 United States55.8%
🇮🇳 India11.6%
🇬🇧 United Kingdom10%
🇨🇦 Canada8.9%
🇳🇱 Netherlands7.9%
Top 5 markets shown

Patent intelligence

$176M patent portfolio · 154 active families

Estimated portfolio value
$176M
1.5% of market cap · 11.5× smaller than top peer Ablynx ($2B)
154 active patent families
Where Kite Pharma innovates Molecular biologyCell therapyCell biologyAntigen receptorsAntigen binding

Where Kite Pharma concentrates vs peers

Each axis is a top-10 topic across Kite Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Kite Pharma's 14 investments and acquisitions.

Every disclosed deal where Kite Pharma appeared as a backer or acquirer, 2016–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

14 deals across Kite Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Kite Pharma deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Kite Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        14 of 14 deals

        Sentiment on X

        What X is saying about Kite Pharma

        An AI-synthesized read of the highest-engagement posts about Kite Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Kite Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles